论文部分内容阅读
目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)患者血清中乙酰肝素酶(heparanase,HPA)和血管内皮生长因子(vascular endothelial growth factor,VEGF)水平检测的意义。方法:56例NSCLC患者纳入研究,以21例健康志愿者为正常对照组,比较分析两组受试者血清中乙酰肝素酶、VEGF水平的差异,并与临床病理特征进行比较分析。结果:在NSCLC患者血清乙酰肝素酶和VEGF水平显著高于正常对照组。在NSCLC患者中,血清乙酰肝素酶和VEGF水平在低分化、临床Ⅲ+Ⅳ期和淋巴结转移阳性患者中较高,与患者性别、年龄、病理类型无关。血清乙酰肝素酶与VEGF水平显著正相关。结论:NSCLC患者血清乙酰肝素酶及VEGF水平显著高于正常水平,与NSCLC的生长、浸润和转移有关,可作为判断NSCLC预后及指导治疗的指标。
Objective: To investigate the significance of detection of heparanase (HPA) and vascular endothelial growth factor (VEGF) in serum of patients with non-small cell lung cancer (NSCLC). Methods: Fifty-six patients with NSCLC were enrolled in this study. Twenty-one healthy volunteers were included in the study. Serum levels of heparanase and VEGF were compared between the two groups, and their clinical and pathological features were compared. Results: Serum levels of heparanase and VEGF in patients with NSCLC were significantly higher than those in the normal controls. Serum heparanase and VEGF levels were higher in patients with poorly differentiated, clinical stage III + IV and lymph node metastasis in patients with NSCLC, regardless of gender, age and pathological type. Serum heparanase was positively correlated with VEGF level. Conclusion: Serum levels of heparanase and VEGF in patients with NSCLC are significantly higher than normal, which are correlated with the growth, invasion and metastasis of NSCLC, which may be used as an index to judge prognosis and guide therapy of NSCLC.